Article
Thyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathway.
The Journal of clinical endocrinology and metabolism - 1 Jun 2013
Frasca Francesco, Vella Veronica, Nicolosi Maria Luisa, Messina Rosa Linda, Gianì Fiorenza, Lotta Sonia, Vigneri Paolo, Regalbuto Concetto, Vigneri Riccardo
Abstract excerpt
CONTEXT: Poorly differentiated thyroid carcinomas are refractory to common anticancer therapies, and novel inhibitors are being tested in these deadly malignancies. The epidermal growth factor receptor (EGFR) tyrosine kinase represents an attractive target for treatment because it is up-regulated...
Topics
- Antineoplastic Agents
- Apoptosis
- Cell Line, Tumor
- Cell Survival
- Drug Resistance, Neoplasm
- Epidermal Growth Factor
- ErbB Receptors
- Gefitinib
- Genes, ras
- Humans
- MAP Kinase Signaling System
- Mutation
- Neoplasm Invasiveness
- Phosphorylation